Abstract
The targeting of specific DNA repair mechanisms may be a promising strategy to improve the efficacy of antitumor therapy. The cytotoxic effects of the clinically relevant topoisomerase 1 (Top1) poison camptothecins are related to the generation of DNA lesions and tumor cells may be resistant to DNA damaging agents due to increased repair. Tyrosyl- DNA phosphodiesterase 1 (TDP1) is implicated in the repair of strand breaks by removing abortive Top1/DNA complexes. Thus, a role for TDP1 in counteracting DNA damage induced by camptothecins has been proposed. Here, we review the role of TDP1 in DNA repair with particular reference to TDP1 function, its cooperation with other pathways and the development of pharmacological inhibitors.
Keywords: Tyrosyl-DNA phosphodiesterase 1, topoisomerase 1, SCAN-1, camptothecin, DNA repair pathways, drug resistance
Current Medicinal Chemistry
Title: Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment
Volume: 17 Issue: 15
Author(s): G. L. Beretta, G. Cossa, L. Gatti, F. Zunino and P. Perego
Affiliation:
Keywords: Tyrosyl-DNA phosphodiesterase 1, topoisomerase 1, SCAN-1, camptothecin, DNA repair pathways, drug resistance
Abstract: The targeting of specific DNA repair mechanisms may be a promising strategy to improve the efficacy of antitumor therapy. The cytotoxic effects of the clinically relevant topoisomerase 1 (Top1) poison camptothecins are related to the generation of DNA lesions and tumor cells may be resistant to DNA damaging agents due to increased repair. Tyrosyl- DNA phosphodiesterase 1 (TDP1) is implicated in the repair of strand breaks by removing abortive Top1/DNA complexes. Thus, a role for TDP1 in counteracting DNA damage induced by camptothecins has been proposed. Here, we review the role of TDP1 in DNA repair with particular reference to TDP1 function, its cooperation with other pathways and the development of pharmacological inhibitors.
Export Options
About this article
Cite this article as:
Beretta L. G., Cossa G., Gatti L., Zunino F. and Perego P., Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment, Current Medicinal Chemistry 2010; 17 (15) . https://dx.doi.org/10.2174/092986710790979971
DOI https://dx.doi.org/10.2174/092986710790979971 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Non-Synonymous Polymorphisms Prediction Methods: Current Approaches and Future Developments
Current Medicinal Chemistry Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Is the Clinical Use of Cannabis by Oncology Patients Advisable?
Current Medicinal Chemistry Liver-Based In Vitro Technologies for Drug Biotransformation Studies - A Review
Current Drug Metabolism Genetic and Environmental Influences on Therapeutic and Toxicity Outcomes: Studies with CYP2A6
Current Clinical Pharmacology Anticancer Activities and Mechanisms of Bisdioxopiperazine Compounds Probimane and MST-16
Anti-Cancer Agents in Medicinal Chemistry Heterocyclic Analogues as Kinase Inhibitors: A Focus Review
Current Topics in Medicinal Chemistry Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design In Vitro and In Vivo Investigations into the Carbene Gold Chloride and Thioglucoside Anticancer Drug Candidates NHC-AuCl and NHC-AuSR
Letters in Drug Design & Discovery Titanium Dioxide Nanoparticles: a Risk for Human Health?
Mini-Reviews in Medicinal Chemistry Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments
Current Pharmaceutical Design Medicinal Chemistry of Probimane and MST-16: Comparison of Anticancer Effects Between Bisdioxopiperazines
Medicinal Chemistry Hepatoma-Derived Growth Factor in Carcinogenesis and Cancer Progression
Current Drug Therapy Evaluation of Salivary Antioxidants and Oxidative Stress Markers in Male Smokers
Combinatorial Chemistry & High Throughput Screening Influence of Biological and Technical Covariates on Non-targeted Metabolite Profiling in a Large-scale Epidemiological Study
Current Metabolomics